Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo.

Carey B, DeLay M, Strasser JE, Chalk C, Dudley-McClain K, Milligan GN, Brunner HI, Thornton S, Hirsch R.

Clin Immunol. 2005 Jul;116(1):65-76.

PMID:
15925833
2.

A divalent major histocompatibility complex/IgG1 fusion protein induces antigen-specific T cell activation in vitro and in vivo.

Cullen CM, Jameson SC, DeLay M, Cottrell C, Becken ET, Choi E, Hirsch R.

Cell Immunol. 1999 Feb 25;192(1):54-62.

PMID:
10066347
3.
4.

Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes.

Oizumi S, Strbo N, Pahwa S, Deyev V, Podack ER.

J Immunol. 2007 Aug 15;179(4):2310-7.

5.

Raising allo-restricted cytotoxic T lymphocytes by co-culture of murine splenocytes with autologous macrophage bearing the peptide/allo-major histococompatibility complex.

Chen X, Yan Y, Lu S, Weng X, Liang Z, Li J, Zhong M, Tang J, Xiao W, Sun W, Shen G, Wu X.

Hum Immunol. 2009 Feb;70(2):79-84. doi: 10.1016/j.humimm.2008.11.005. Epub 2008 Dec 25.

PMID:
19100802
6.

Enhanced generation of cytotoxic T lymphocytes by increased cytosolic delivery of MHC class I epitope fused to mouse heat shock protein 70 via polyhistidine conjugation.

Takemoto S, Nishikawa M, Otsuki T, Yamaoka A, Maeda K, Ota A, Takakura Y.

J Control Release. 2009 Apr 2;135(1):11-8. doi: 10.1016/j.jconrel.2008.11.024. Epub 2008 Dec 3.

PMID:
19100299
7.
9.

Herpes simplex virus type 1-specific cytotoxic T-lymphocyte arming occurs within lymph nodes draining the site of cutaneous infection.

Jones CM, Cose SC, Coles RM, Winterhalter AC, Brooks AG, Heath WR, Carbone FR.

J Virol. 2000 Mar;74(5):2414-9.

10.

Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1.

Coles RM, Mueller SN, Heath WR, Carbone FR, Brooks AG.

J Immunol. 2002 Jan 15;168(2):834-8.

11.

Cutting edge: priming of CD8 T cell immunity to herpes simplex virus type 1 requires cognate TLR3 expression in vivo.

Davey GM, Wojtasiak M, Proietto AI, Carbone FR, Heath WR, Bedoui S.

J Immunol. 2010 Mar 1;184(5):2243-6. doi: 10.4049/jimmunol.0903013. Epub 2010 Feb 1.

12.

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.

Clin Immunol. 2009 Nov;133(2):184-97. doi: 10.1016/j.clim.2009.07.008. Epub 2009 Aug 7.

PMID:
19664962
13.

Virus infection expands a biased subset of T cells that bind tetrameric class I peptide complexes.

Coles RM, Jones CM, Brooks AG, Cameron PU, Heath WR, Carbone FR.

Eur J Immunol. 2003 Jun;33(6):1557-67.

14.

Both CD4+ and CD8+ T cells respond to antigens fused to anthrax lethal toxin.

Shaw CA, Starnbach MN.

Infect Immun. 2008 Jun;76(6):2603-11. doi: 10.1128/IAI.01718-07. Epub 2008 Mar 17.

15.

Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors.

Mizukami S, Kajiwara C, Ishikawa H, Katayama I, Yui K, Udono H.

Cancer Sci. 2008 May;99(5):1008-15. doi: 10.1111/j.1349-7006.2008.00788.x. Epub 2008 Mar 12.

16.

Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.

Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.

Eur J Immunol. 2009 Oct;39(10):2725-36. doi: 10.1002/eji.200939543.

17.

Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.

Liu A, Hu P, Khawli LA, Epstein AL.

Clin Cancer Res. 2005 Dec 1;11(23):8492-502.

18.

[Coreceptor function of CD4 in response to MHC class I molecule].

Zvezdova ES, Grinenko TS, Pobezinskaia EL, Pobezinskiń≠ LA, Kazanskiń≠ DB.

Mol Biol (Mosk). 2008 Jul-Aug;42(4):662-72. Russian.

PMID:
18856067
20.

An efficient and versatile mammalian viral vector system for major histocompatibility complex class I/peptide complexes.

Kawana-Tachikawa A, Tomizawa M, Nunoya J, Shioda T, Kato A, Nakayama EE, Nakamura T, Nagai Y, Iwamoto A.

J Virol. 2002 Dec;76(23):11982-8.

Supplemental Content

Support Center